Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates

 
• By Mandy Jackson

The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.

Signpost outside is showing Phase 1 and Phase 2
Neurimmune is transitioning from a Phase I to a Phase II company • Source: Shutterstock

More from Strategy

More from Business